CTLA4 and neoplasm: Altogether, our results could indicate that, unlike other tumor types, chemotherapy and/or antiangiogenic agents might not be the preferred candidates to associate with anti-PD(L)1 monoclonal antibodies in dMMR/MSI mCRC, for which combinations with anti-cytotoxic T lymphocyte antigen 4 (CTLA4) antibodies or other molecules under development targeting putative immune checkpoints (such as LAG3, TIM3, TIGIT ...) might represent a more promising approach for the future.